Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
29 oct. 2014 16h01 HE
|
Receptos, Inc.
SAN DIEGO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
27 oct. 2014 16h01 HE
|
Receptos, Inc.
– Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment –
– Safety data are consistent...
Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
03 oct. 2014 08h00 HE
|
Receptos, Inc.
SAN DIEGO, Oct. 3, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Announces Oral Podium Presentation at MS Boston 2014
10 sept. 2014 08h00 HE
|
Receptos, Inc.
Detailed Results of Positive Phase 2 Trial of RPC1063 in Relapsing Multiple Sclerosis to be Presented at Late Breaker Session on September 13, 2014
Company to Host Investor Call and Webcast on...
Receptos Reports Second Quarter 2014 Financial Results
12 août 2014 07h30 HE
|
Receptos, Inc.
Completes enrollment of Phase 2 trial of RPC1063 in Ulcerative Colitis; data expected in fourth quarter of 2014
Announces oral platform presentation of Phase 2 data for RPC1063 in Relapsing...
Receptos to Present at Wedbush PacGrow Life Sciences Conference
08 août 2014 08h00 HE
|
Receptos, Inc.
SAN DIEGO, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Hold Second Quarter 2014 Financial Results Conference Call and Webcast
07 août 2014 16h01 HE
|
Receptos, Inc.
SAN DIEGO, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors
29 juil. 2014 08h00 HE
|
Receptos, Inc.
SAN DIEGO, July 29, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Announces Closing of Underwritten Public Offering of Common Stock
24 juin 2014 09h34 HE
|
Receptos, Inc.
SAN DIEGO, June 24, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
18 juin 2014 19h42 HE
|
Receptos, Inc.
SAN DIEGO, June 18, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...